Real-time Quotes | Nasdaq Last Sale

Pre Market: 1.910 -0.01 -0.52% 07:07 11/24 EST
Corp Actions
vTv Therapeutics reports Q3 results
vTv Therapeutics (VTVT): Q3 GAAP EPS of -$0.03.Revenue of $0.01M.Cash position of $1.8M. Press Release
Seekingalpha · 11/05 22:34
vTv Therapeutics Q3 EPS $(0.03) Up From $(0.10) YoY
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.03) per share. This is a 70 percent increase over losses of $(0.10) per share from the same period last year.
Benzinga · 11/05 21:59
Banco Bilbao Vizcaya Argentaria, Alliance Resource Partners leads premarket losers' pack
RealNetworks (RNWK) -12% on Q3 earnings release.Aptevo Therapeutics (APVO) -12%.vTv Therapeutics (VTVT) -8% on reporting baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azeliragon as a potential treatment for mild Alzheimer’s
Seekingalpha · 11/04 13:25
VTv Therapeutics' Elevage study suggests comparability to diabetes subgroup of Phase 3 STEADFAST study
VTv Therapeutics (VTVT) reports baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azeliragon as a potential treatment for mild Alzheimer’s disease ((AD)) in people with
Seekingalpha · 11/04 12:56
vTv Therapeutics, Forte Biosciences leads healthcare gainers; Tricida, Cancer Genetics among major losers
Gainers: vTv Therapeutics (VTVT) +22%, Forte Biosciences (FBRX) +20%, Penumbra (PEN) +14%, Cellect Biotechnology (APOP) +10%, Inari Medical (NARI) +10%.Losers: Tricida (TCDA) -52%, Cancer Genetics (CGIX) -34%., Constellation Pharmaceuticals (CNST) -17%, Miragen Therapeutics (MGEN) -7%, Inovalon Holdings (INOV) -15%.
Seekingalpha · 10/29 15:03
vTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimers Disease (CTAD) Digital Event
HIGH POINT, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that it will make an oral presentation at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event on November 4, 2020. The presentation will provide a general study update and data on the baseline characteristics of patients enrolled in the ongoing phase 2 Elevage Study of azeliragon as a potential treatment for mild-probable Alzheimer’s disease (AD) in adult patients who also have type 2 diabetes. Patient enrollment in the Elevage Study concluded as of September 2020 and vTv expects to report topline results in December 2020. Details of the CTAD digital presentation are:Oral Presentation Title: “The Azeliragon Elevage Study: Study Update and Preliminary Data on Baseline Characteristics of Participants with Mild Alzheimer’s Disease and Type 2 Diabetes Randomized in Part 1” Presentation Number: LB5 Category: On Demand, Late Breaking Communications Date and Time: Wednesday, November 4, 2020, Available from 1 am US EST About the Elevage Study The Elevage Study is a randomized, double-blind, placebo-controlled clinical trial evaluating azeliragon in individuals ages 50 – 85 with probable mild-Alzheimer’s disease and type 2 diabetes. The objective of the Elevage Study is to replicate in a randomized double-blind, placebo controlled study the results observed in a post hoc analysis of the phase 3 STEADFAST trial A-Study in which a subgroup of forty-seven (47) patients with mild Alzheimer’s disease and type 2 diabetes treated with azeliragon demonstrated nominally statistically significant improvements in cognition on the ADAS-cog11 scale of 5.5 points (p=0.006) at month 18 compared to the same subgroup of patients treated with placebo. Azeliragon associated improvement was nominally significant as early as month 6 on the ADAS-cog11 scale (4.9 points, p<0.001).About vTv Therapeutics vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes, Alzheimer’s disease, and inflammatory disorders. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), and genetic mitochondrial diseases. For more information, please visit or follow us on Twitter: @vTvTherapeutics.Forward-Looking Statements This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.Contacts Investors: Corey Davis LifeSci Advisors CDavis@LifeSciAdvisors.comorMedia: Glenn Silver Lazar FINN Partners 646-871-8485
GlobeNewswire · 10/29 12:30
vTv Therapeutics To Present Study Update And Preliminary Data On Baseline Characteristics Of Study Participants In Phase 2 Elevage Study Evaluating Azeliragon At 13th Clinical Trials On Alzheimer's Disease (CTAD) Digital Event
HIGH POINT, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT) today announced that it will make an oral presentation at the 13th Clinical Trials on Alzheimer's Disease (CTAD)
Benzinga · 10/29 11:43
NKE, WDC among premarket gainers
SPI Energy (SPI) +56% after launching new EV Company.MediciNova (MNOV) +36% on positive intranasal COVID-19 vaccine data.vTv Therapeutics (VTVT) +20% on positive clinical study results supporting the safety and efficacy of TTP399.Athersys (ATHX) +13% after FDA grants RMAT
Seekingalpha · 09/23 12:19
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VTVT. Analyze the recent business situations of VTV THERAPEUTICS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VTVT stock price target is 7.00 with a high estimate of 8.00 and a low estimate of 6.00.
Institutional Holdings
Institutions: 57
Institutional Holdings: 4.40M
% Owned: 5.96%
Shares Outstanding: 73.88M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Biotechnology & Medical Research
Pharmaceuticals & Medical Research
Key Executives
Jeffrey Kindler
President/Chief Executive Officer
Stephen Holcombe
Chief Financial Officer/Executive Vice President
Rudy Howard
Hersh Kozlov
Richard Nelson
Independent Director
John Fry
Independent Director
Noel Spiegel
Independent Director
Howard Weiner
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Hot Stocks

Webull offers kinds of vTv Therapeutics Inc stock information, including NASDAQ:VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.